# US 2021/0079017 A1 · Neprilysin inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079017 A1
- Document ID: US20210079017A1
- Status: Published application
- Kind: A1
- Application number: 16/947,214
- Filed: 2020-07-23
- Published: 2021-03-18
- Earliest claimed: 2010-12-15
- Assignees: Theravance Biopharma R&D IP, LLC
- Applicants: Theravance Biopharma R&D IP, LLC
- Inventors: Roland Gendron; Melissa Fleury; Adam D. Hughes
- Web page: https://patentgrep.com/patent/US20210079017A1

## CPC

- C07D 498/08: Bridged systems
- A61K 31/42: Oxazoles
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/12: Antidiarrhoeals
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 207/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 213/79: Acids; Esters
- C07D 213/80: in position 3
- C07D 213/81: Amides; Imides
- C07D 231/14: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 233/26: Radicals substituted by carbon atoms having three bonds to hetero atoms
- C07D 233/90: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 237/04: having less than three double bonds between ring members or between ring members and non-ring members
- C07D 237/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 239/34: One oxygen atom
- C07D 239/36: as doubly bound oxygen atom or as unsubstituted hydroxy radical
- C07D 241/24: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 249/04: 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D 249/10: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 249/12: Oxygen or sulfur atoms
- C07D 249/18: Benzotriazoles
- C07D 257/04: Five-membered rings
- C07D 261/12: Oxygen atoms
- C07D 261/18: Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- C07D 261/20: condensed with carbocyclic rings or ring systems
- C07D 263/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 263/56: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D 277/46: by carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D 277/56: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 307/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 333/40: Thiophene-2-carboxylic acid
- C07D 333/70: attached in position 2
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A method of treating a disease mediated at least in part by neprilysin in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from —OR7 and —NR8R9;
R2 is selected from H and —P(O)(OH)2;
X is —C1-9heteroaryl;
R3 is absent or is selected from H; halo; —C0-5alkylene-OH; —NH2; —C1-6alkyl; —CF3; —C3-7cycloalkyl; —C0-2alkylene-O—C1-6alkyl; —C(O)R20; —C0-1alkylene-COOR21; —C(O)NR22R23; —NHC(O)R24; ═O; —NO2; —C(CH3)═N(OH); phenyl, optionally substituted with one or two groups independently selected from halo, —OH, —CF3, —OCH3, —NHC(O)CH3, and phenyl; naphthalenyl; pyridinyl; pyrazinyl; pyrazolyl, optionally substituted with methyl; thiophenyl, optionally substituted with methyl or halo; furanyl; and —CH2-morpholinyl; wherein R3, when present, is attached to a carbon atom;
R4 is absent or is selected from H; —OH; —C1-6alkyl; —C1-2alkylene-COOR35; —CH2OC(O)CH(R36)NH2; —OCH2OC(O)CH(R36)NH2; —OCH2OC(O)CH3; —CH2OP(O)(OH)2; —CH2CH(OH)CH2OH; —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl; pyridinyl; and phenyl or benzyl, each of which is optionally substituted with one or more groups selected from halo, —COOR35, —OCH3, —OCF3, and —SCF3; wherein R4, when present, is attached to a carbon or nitrogen atom;
a is 0 or 1;
R5 is selected from halo, —CH3, —CF3, and —CN;
b is 0 or an integer from 1 to 3;
each R6 is independently selected from halo, —OH, —CH3, —OCH3, and —CF3;
R7 is selected from H, —C1-8alkyl, —C1-3alkylene-C6-10aryl, —C1-3alkylene-C1-9heteroaryl, —C3-7cycloalkyl, —[(CH2)2O]1-3CH3, —C1-6alkylene-OC(O)R10, —C1-6alkylene-NR12R13, —C1-6alkylene-C(O)R31, —C0-6alkylenemorpholinyl, —C1-6alkylene-SO2—C1-6alkyl,
R10 is selected from —C1-6alkyl, —O—C1-6alkyl, —C3-7cycloalkyl, —O—C3-7cycloalkyl, phenyl, —O-phenyl, —NR12R13, —CH[CH(CH3)2]—NH2, —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl, and —CH(NH2)CH2COOCH3;
R12 and R13 are independently selected from H, —C1-6alkyl, and benzyl; or
R12 and R13 are taken together as —(CH2)3-6—, —C(O)—(CH2)3—, or —(CH2)2O(CH2)2—;
R31 is selected from —O—C1-6alkyl, —O-benzyl, and —NR12R13;
R32 is selected from —C1-6alkyl and —C0-6alkylene-C6-10aryl;
R8 is selected from H, —OH, —OC(O)R14, —CH2COOH, —O-benzyl, -pyridyl, and —OC(S)NR15R16;
R14 is selected from H, —C1-6alkyl, —C6-10aryl, —OCH2—C6-10aryl, —CH2O—C6-10aryl, and —NR15R16;
R15 and R16 are independently selected from H and —C1-4alkyl;
R9 is selected from H, —C1-6alkyl, and —C(O)—R17;
R17 is selected from H, —C1-6alkyl, —C3-7cycloalkyl, —C6-10aryl, and —C1-9heteroaryl;
R20 is selected from H and —C1-6alkyl;
R21 and R35 are independently selected from H, —C1-6alkyl, —C1-3alkylene-C6-10aryl, —C1-3alkylene-C1-9heteroaryl, —C3-7cycloalkyl, —[(CH2)2O]1-3CH3, —C1-6alkylene-OC(O)R25, —C1-6alkylene-NR27R28, —C1-6alkylene-C(O)R33, —C0-6alkylenemorpholinyl, —C1-6alkylene-SO2—C1-6alkyl,
R25 is selected from —C1-6alkyl, —O—C1-6alkyl, —C3-7cycloalkyl, —O—C3-7cycloalkyl, phenyl, —O-phenyl, —NR27R28, —CH[CH(CH3)2]—NH2, —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl, and —CH(NH2)CH2COOCH3;
R27 and R28 are independently selected from H, —C1-6alkyl, and benzyl; or
R27 and R28 are taken together as —(CH2)3-6—, —C(O)—(CH2)3—, or —(CH2)2O(CH2)2—;
R33 is selected from —O—C1-6alkyl, —O-benzyl, and —NR27R28;
R34 is selected from —C1-6alkyl and —C0-6alkylene-C6-10aryl;
R22 and R23 are independently selected from H, —C1-6alkyl, —CH2COOH, —(CH2)2OH, —(CH2)2OCH3, —(CH2)2SO2NH2, —(CH2)2N(CH3)2, —C0-1alkylene-C3-7cycloalkyl, and —(CH2)2-imidazolyl; or
R22 and R23 are taken together to form a saturated or partially unsaturated —C3-5heterocycle, optionally substituted with halo, —OH, —COOH, or —CONH2;
R24 is selected from —C1-6alkyl; —C0-1alkylene-O—C1-6alkyl; phenyl, optionally substituted with halo or —OCH3; and —C1-9heteroaryl; and
R36 is selected from H, —CH(CH3)2, phenyl, and benzyl;
wherein each alkyl group in R1, R3, and R4 is optionally substituted with 1 to 8 fluoro atoms; and
wherein the methylene linker on the biphenyl is optionally substituted with one or two —C1-6alkyl groups or cyclopropyl.

### Claim 30 (depends on 29)

The method of claim 29, wherein the disease is selected from hypertension, heart failure, and renal disease.

### Claim 31 (depends on 29)

The method of claim 29, further comprising administering a therapeutic agent selected from an AT1 receptor antagonist, an angiotensin-converting enzyme inhibitor, a phosphodiesterase inhibitor, a renin inhibitor, and a diuretic, or a combination thereof.

### Claim 32 (depends on 29)

The method of claim 29, further comprising administering an AT1 receptor antagonist, wherein the AT1 receptor antagonist is selected from abitesartan, azilsartan, azilsartan medoxomil, benzyllosartan, candesartan, candesartan cilexetil, elisartan, embusartan, enoltasosartan, eprosartan, EXP3174, fonsartan, forasartan, glycyllosartan, irbesartan, isoteoline, losartan, milfasartan, olmesartan, olmesartan medoxomil, opomisartan, pratosartan, ripisartan, saprisartan, saralasin, sarmesin, TAK-591, tasosartan, telmisartan, valsartan, and zolasartan.

### Claim 33 (depends on 29)

The method of claim 29, wherein R1 is —OR7; and R7 is selected from H and —C1-8alkyl.

### Claim 34 (depends on 29)

The method of claim 29, wherein R2 is H.

### Claim 35 (depends on 29)

The method of claim 29, wherein X is selected from oxazole and isoxazole.

### Claim 36 (depends on 29)

The method of claim 29, wherein R3 is selected from H, —C0-5alkylene-OH, —C1-6alkyl, and —C0-2alkylene-O—C1-6alkyl; and R4 is H.

### Claim 37 (depends on 29)

The method of claim 29, wherein a is 0; b is 0, 1 or 2; and each R6 is independently selected from halo.

### Claim 38 (depends on 29)

The method of claim 29, wherein R1 is —OR7; R7 is selected from H and —C1-8 alkyl; R2 is H; X is selected from oxazole and isoxazole; R3 is selected from H, —C0-5alkylene-OH, —C1-6alkyl, and —C0-2alkylene-O—C1-6alkyl; R4 is H; a is 0; b is 0, 1 or 2; and each R6 is independently selected from halo.

### Claim 39 (depends on 29)

The method of claim 29, wherein the compound of Formula (I) is a compound of Formula (Ia):
or a pharmaceutically acceptable salt thereof.

### Claim 40 (depends on 39)

The method of claim 39, wherein R1 is —OR7; R7 is selected from H and —C1-8 alkyl; R2 is H; X is selected from oxazole and isoxazole; R3 is selected from H, —C0-5alkylene-OH, —C1-6alkyl, and —C0-2alkylene-O—C1-6alkyl; R4 is H; a is 0; b is 0, 1 or 2; and each R6 is independently selected from halo.

### Claim 41 (depends on 29)

The method of claim 29, wherein the compound of Formula (I) is a compound of the formula:
or a pharmaceutically acceptable salt thereof.

### Claim 42 (depends on 41)

The method of claim 41, wherein R1 is —OR7; R7 is selected from H and —C1-8 alkyl; R2 is H; X is selected from oxazole and isoxazole; R3 is selected from H, —C0-5alkylene-OH, —C1-6alkyl, and —C0-2alkylene-O—C1-6alkyl; and R4 is H.

### Claim 43 (depends on 29)

The method of claim 29, wherein the compound is selected from:
(2R,4R)-5-biphenyl-4-yl-2-hydroxy-4-[(3-hydroxyisoxazole-5-carbonyl)amino]pentanoic acid ethyl ester;
(2R,4R)-5-biphenyl-4-yl-2-hydroxy-4-[(3-hydroxyisoxazole-5-carbonyl)amino]pentanoic acid;
(2R,4R)-5-biphenyl-4-yl-2-hydroxy-4-[(3-methoxyisoxazole-5-carbonyl)amino]-pentanoic acid;
(2R,4R)-5-(3′-chlorobiphenyl-4-yl)-2-hydroxy-4-[(3-methoxy-isoxazole-5-carbonyl)-amino]-pentanoic acid;
(2R,4R)-5-(3′-chloro-biphenyl-4-yl)-2-hydroxy-4-[(3-isopropyl-isoxazole-5-carbonyl)-amino]-pentanoic acid;
(2R,4R)-5-(3′-chloro-biphenyl-4-yl)-2-hydroxy-4-[(3-propyl-isoxazole-5-carbonyl)-amino]-pentanoic acid;
(2R,4R)-5-(3′-chloro-biphenyl-4-yl)-2-hydroxy-4-[(3-isobutyl-isoxazole-5-carbonyl)-amino]-pentanoic acid;
(2R,4R)-5-(3′-chloro-biphenyl-4-yl)-2-hydroxy-4-{[3-(1-hydroxy-1-methyl-ethyl)-isoxazole-5-carbonyl]-amino}-pentanoic acid;
(2R,4R)-4-[(3-tert-butyl-isoxazole-5-carbonyl)-amino]-5-(3′-chloro-biphenyl-4-yl)-2-hydroxy-pentanoic acid;
(2R,4R)-5-(5′-chloro-2′-fluoro-biphenyl-4-yl)-2-hydroxy-4-[(3-methoxy-isoxazole-5-carbonyl)-amino]-pentanoic acid; and
(2R,4S)-5-biphenyl-4-yl-2-hydroxy-4-[(3-hydroxy-isoxazole-5-carbonyl)-amino]-5-methyl-hexanoic acid,
or a pharmaceutically acceptable salt thereof.

### Claim 44

A method of inhibiting activity of a neprilysin enzyme, comprising contacting the neprilysin enzyme with a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from —OR7 and —NR8R9;
R2 is selected from H and —P(O)(OH)2;
X is —C1-9heteroaryl;
R3 is absent or is selected from H; halo; —C0-5alkylene-OH; —NH2; —C1-6alkyl; —CF3; —C3-7cycloalkyl; —C0-2alkylene-O—C1-6alkyl; —C(O)R20; —C0-1alkylene-COOR21; —C(O)NR22R23; —NHC(O)R24; ═O; —NO2; —C(CH3)═N(OH); phenyl, optionally substituted with one or two groups independently selected from halo, —OH, —CF3, —OCH3, —NHC(O)CH3, and phenyl; naphthalenyl; pyridinyl; pyrazinyl; pyrazolyl, optionally substituted with methyl; thiophenyl, optionally substituted with methyl or halo; furanyl; and —CH2-morpholinyl; wherein R3, when present, is attached to a carbon atom;
R4 is absent or is selected from H; —OH; —C1-6alkyl; —C1-2alkylene-COOR35; —CH2OC(O)CH(R36)N-2; —OCH2OC(O)CH(R36)N-2; —OCH2OC(O)CH3; —CH2OP(O)(OH)2; —CH2CH(OH)CH2OH; —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl; pyridinyl; and phenyl or benzyl, each of which is optionally substituted with one or more groups selected from halo, —COOR35, —OCH3, —OCF3, and —SCF3; wherein R4, when present, is attached to a carbon or nitrogen atom;
a is 0 or 1;
R5 is selected from halo, —CH3, —CF3, and —CN;
b is 0 or an integer from 1 to 3;
each R6 is independently selected from halo, —OH, —CH3, —OCH3, and —CF3;
R7 is selected from H, —C1-8alkyl, —C1-3alkylene-C6-10aryl, —C1-3alkylene-C1-9heteroaryl, —C3-7cycloalkyl, —[(CH2)2O]1-3CH3, —C1-6alkylene-OC(O)R10, —C1-6alkylene-NR12R13, —C1-6alkylene-C(O)R31, —C0-6alkylenemorpholinyl, —C1-6alkylene-SO2—C1-6alkyl,
R10 is selected from —C1-6alkyl, —O—C1-6alkyl, —C3-7cycloalkyl, —O—C3-7cycloalkyl, phenyl, —O-phenyl, —NR12R13, —CH[CH(CH3)2]—NH2, —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl, and —CH(NH2)CH2COOCH3;
R12 and R13 are independently selected from H, —C1-6alkyl, and benzyl; or
R12 and R13 are taken together as —(CH2)3-6—, —C(O)—(CH2)3—, or —(CH2)2O(CH2)2—;
R31 is selected from —O—C1-6alkyl, —O-benzyl, and —NR12R13;
R32 is selected from —C1-6alkyl and —C0-6alkylene-C6-10aryl;
R8 is selected from H, —OH, —OC(O)R14, —CH2COOH, —O-benzyl, -pyridyl, and —OC(S)NR15R16;
R14 is selected from H, —C1-6alkyl, —C6-10aryl, —OCH2—C6-10aryl, —CH2O—C6-10aryl, and —NR15R16,
R15 and R16 are independently selected from H and —C1-4alkyl;
R9 is selected from H, —C1-6alkyl, and —C(O)—R17;
R17 is selected from H, —C1-6alkyl, —C3-7cycloalkyl, —C6-10aryl, and —C1-9heteroaryl;
R20 is selected from H and —C1-6alkyl;
R21 and R35 are independently selected from H, —C1-6alkyl, —C1-3alkylene-C6-10aryl, —C1-3alkylene-C1-9heteroaryl, —C3-7cycloalkyl, —[(CH2)2O]1-3CH3, —C1-6alkylene-OC(O)R25, —C1-6alkylene-NR27R28, —C1-6alkylene-C(O)R33, —C0-6alkylenemorpholinyl, —C1-6alkylene-SO2—C1-6alkyl,
R25 is selected from —C1-6alkyl, —O—C1-6alkyl, —C3-7cycloalkyl, —O—C3-7cycloalkyl, phenyl, —O-phenyl, —NR27R28, —CH[CH(CH3)2]—NH2, —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl, and —CH(NH2)CH2COOCH3;
R27 and R28 are independently selected from H, —C1-6alkyl, and benzyl; or
R27 and R28 are taken together as —(CH2)3-6—, —C(O)—(CH2)3—, or —(CH2)2O(CH2)2—;
R33 is selected from —O—C1-6alkyl, —O-benzyl, and —NR27R28;
R34 is selected from —C1-6alkyl and —C0-6alkylene-C6-10aryl;
R22 and R23 are independently selected from H, —C1-6alkyl, —CH2COOH, —(CH2)2OH, —(CH2)2OCH3, —(CH2)2SO2NH2, —(CH2)2N(CH3)2, —C0-1alkylene-C3-7cycloalkyl, and —(CH2)2-imidazolyl; or
R22 and R23 are taken together to form a saturated or partially unsaturated —C3-5heterocycle, optionally substituted with halo, —OH, —COOH, or —CONH2;
R24 is selected from —C1-6alkyl; —C0-1alkylene-O—C1-6alkyl; phenyl, optionally substituted with halo or —OCH3; and —C1-9heteroaryl; and
R36 is selected from H, —CH(CH3)2, phenyl, and benzyl;
wherein each alkyl group in R1, R3, and R4 is optionally substituted with 1 to 8 fluoro atoms; and
wherein the methylene linker on the biphenyl is optionally substituted with one or two —C1-6alkyl groups or cyclopropyl.

### Claim 45 (depends on 44)

The method of claim 44, wherein R1 is —OR7; R7 is selected from H and —C1-8 alkyl; R2 is H; X is selected from oxazole and isoxazole; R3 is selected from H, —C0-5alkylene-OH, —C1-6alkyl, and —C0-2alkylene-O—C1-6alkyl; R4 is H; a is 0; b is 0, 1 or 2; and each R6 is independently selected from halo.

### Claim 46

A method of treating hypertension, heart failure, or renal disease in a subject in need thereof, comprising administering to the subject an AT1 receptor antagonist and an effective amount of a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from —OR7 and —NR8R9;
R2 is selected from H and —P(O)(OH)2;
X is —C1-9heteroaryl;
R3 is absent or is selected from H; halo; —C0-5alkylene-OH; —NH2; —C1-6alkyl; —CF3; —C3-7cycloalkyl; —C0-2alkylene-O—C1-6alkyl; —C(O)R20; —C0-1alkylene-COOR21; —C(O)NR22R23; —NHC(O)R24; ═O; —NO2; —C(CH3)═N(OH); phenyl, optionally substituted with one or two groups independently selected from halo, —OH, —CF3, —OCH3, —NHC(O)CH3, and phenyl; naphthalenyl; pyridinyl; pyrazinyl; pyrazolyl, optionally substituted with methyl; thiophenyl, optionally substituted with methyl or halo; furanyl; and —CH2-morpholinyl; wherein R3, when present, is attached to a carbon atom;
R4 is absent or is selected from H; —OH; —C1-6alkyl; —C1-2alkylene-COOR35; —CH2OC(O)CH(R36)N-2; —OCH2OC(O)CH(R36)N-2; —OCH2OC(O)CH3; —CH2OP(O)(OH)2; —CH2CH(OH)CH2OH; —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl; pyridinyl; and phenyl or benzyl, each of which is optionally substituted with one or more groups selected from halo, —COOR35, —OCH3, —OCF3, and —SCF3; wherein R4, when present, is attached to a carbon or nitrogen atom;
a is 0 or 1;
R5 is selected from halo, —CH3, —CF3, and —CN;
b is 0 or an integer from 1 to 3;
each R6 is independently selected from halo, —OH, —CH3, —OCH3, and —CF3;
R7 is selected from H, —C1-8alkyl, —C1-3alkylene-C6-10aryl, —C1-3alkylene-C1-9heteroaryl, —C3-7cycloalkyl, —[(CH2)2O]1-3CH3, —C1-6alkylene-OC(O)R10, —C1-6alkylene-NR12R13, —C1-6alkylene-C(O)R31, —C0-6alkylenemorpholinyl, —C1-6alkylene-SO2—C1-6alkyl,
R10 is selected from —C1-6alkyl, —O—C1-6alkyl, —C3-7cycloalkyl, —O—C3-7cycloalkyl, phenyl, —O-phenyl, —NR12R13, —CH[CH(CH3)2]—NH2, —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl, and —CH(NH2)CH2COOCH3;
R12 and R13 are independently selected from H, —C1-6alkyl, and benzyl; or
R12 and R13 are taken together as —(CH2)3-6—, —C(O)—(CH2)3—, or —(CH2)2O(CH2)2—;
R31 is selected from —O—C1-6alkyl, —O-benzyl, and —NR12R13;
R32 is selected from —C1-6alkyl and —C0-6alkylene-C6-10aryl;
R8 is selected from H, —OH, —OC(O)R14, —CH2COOH, —O-benzyl, -pyridyl, and —OC(S)NR15R16;
R14 is selected from H, —C1-6alkyl, —C6-10aryl, —OCH2—C6-10aryl, —CH2O—C6-10aryl, and —NR15R16,
R15 and R16 are independently selected from H and —C1-4alkyl;
R9 is selected from H, —C1-6alkyl, and —C(O)—R17;
R17 is selected from H, —C1-6alkyl, —C3-7cycloalkyl, —C6-10aryl, and —C1-9heteroaryl;
R20 is selected from H and —C1-6alkyl;
R21 and R35 are independently selected from H, —C1-6alkyl, —C1-3alkylene-C6-10aryl, —C1-3alkylene-C1-9heteroaryl, —C3-7cycloalkyl, —[(CH2)2O]1-3CH3, —C1-6alkylene-OC(O)R25, —C1-6alkylene-NR27R28, —C1-6alkylene-C(O)R33, —C0-6alkylenemorpholinyl, —C1-6alkylene-SO2—C1-6alkyl,
R25 is selected from —C1-6alkyl, —O—C1-6alkyl, —C3-7cycloalkyl, —O—C3-7cycloalkyl, phenyl, —O-phenyl, —NR27R28, —CH[CH(CH3)2]—NH2, —CH[CH(CH3)2]—NHC(O)O—C1-6alkyl, and —CH(NH2)CH2COOCH3;
R27 and R28 are independently selected from H, —C1-6alkyl, and benzyl; or
R27 and R28 are taken together as —(CH2)3-6—, —C(O)—(CH2)3—, or —(CH2)2O(CH2)2—;
R33 is selected from —O—C1-6alkyl, —O-benzyl, and —NR27R28;
R34 is selected from —C1-6alkyl and —C0-6alkylene-C6-10aryl;
R22 and R23 are independently selected from H, —C1-6alkyl, —CH2COOH, —(CH2)2OH, —(CH2)2OCH3, —(CH2)2SO2NH2, —(CH2)2N(CH3)2, —C0-1alkylene-C3-7cycloalkyl, and —(CH2)2-imidazolyl; or
R22 and R23 are taken together to form a saturated or partially unsaturated —C3-5heterocycle, optionally substituted with halo, —OH, —COOH, or —CONH2;
R24 is selected from —C1-6alkyl; —C0-1alkylene-O—C1-6alkyl; phenyl, optionally substituted with halo or —OCH3; and —C1-9heteroaryl; and
R36 is selected from H, —CH(CH3)2, phenyl, and benzyl;
wherein each alkyl group in R1, R3, and R4 is optionally substituted with 1 to 8 fluoro atoms; and
wherein the methylene linker on the biphenyl is optionally substituted with one or two —C1-6alkyl groups or cyclopropyl.

### Claim 47 (depends on 46)

The method of claim 46, wherein the AT1 receptor antagonist is selected from abitesartan, azilsartan, azilsartan medoxomil, benzyllosartan, candesartan, candesartan cilexetil, elisartan, embusartan, enoltasosartan, eprosartan, EXP3174, fonsartan, forasartan, glycyllosartan, irbesartan, isoteoline, losartan, milfasartan, olmesartan, olmesartan medoxomil, opomisartan, pratosartan, ripisartan, saprisartan, saralasin, sarmesin, TAK-591, tasosartan, telmisartan, valsartan, and zolasartan.

### Claim 48 (depends on 46)

The method of claim 46, wherein R1 is —OR7; R7 is selected from H and —C1-8 alkyl; R2 is H; X is selected from oxazole and isoxazole; R3 is selected from H, —C0-5alkylene-OH, —C1-6alkyl, and —C0-2alkylene-O—C1-6alkyl; R4 is H; a is 0; b is 0, 1 or 2; and each R6 is independently selected from halo.
